Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | CCR3 | P51677 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7368940 | 0.91 | CCR3 (0.38) | DPP4DPP8DPP9DPP7MAOB | |
| SCHEMBL7360568 | 0.91 | DPP4 (0.36) | DPP4MAOBSLC6A2SLC6A4CCR3 | |
| SCHEMBL7366933 | 0.90 | SIGMAR1 (0.33) | DPP4DPP8DPP9DPP7SIGMAR1 | |
| SCHEMBL7361665 | 0.90 | GAA (0.36) | DPP4 | |
| SCHEMBL7364616 | 0.80 | GAA (0.39) | DPP4 | |
| SCHEMBL3140691 | 0.76 | MAOB (0.39) | DPP4DPP8DPP9DPP7MAOB | |
| SCHEMBL3258336 | 0.76 | MAOB (0.39) | DPP4DPP8DPP9DPP7MAOB | |
| SCHEMBL7434422 | 0.75 | ALDH1A1 (0.39) | F2 | |
| SCHEMBL7359248 | 0.75 | ALDH1A1 (0.39) | F2 | |
| SCHEMBL3145715 | 0.73 | MAOB (0.37) | DPP4DPP8DPP9DPP7MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1997046553-A1 | THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | disclosed |